$5.1B deal: GSK to buy Boston-area cancer drug developer By: Philadelphia Business Journal via Business Journals December 03, 2018 at 09:35 AM EST GSK is offering $75 a share for the biopharm concern that has developed an ovarian cancer therapy being tested for other types of cancers. Read More >> Related Stocks: Gsk Plc ADR